文献速递神经免疫神经重症与神经感染

免疫检查点抑制剂诱导的脑炎:系统综述

Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
PubMed 文献 · JAMA Neurol · 2021-01-01

该系统综述汇总了77例文献病例和5例医疗记录,共82例免疫检查点抑制剂诱导的脑炎(ICI-iE)患者。多数表现为局灶综合征或脑膜脑炎,总体预后良好,但伴有其他自身抗体或局灶综合征者预后较差。临床表现和自身抗体检测有助于预后判断和治疗策略。

要点

  • ICI-iE主要表现为局灶性(边缘或边缘外)脑炎或脑膜脑炎两种综合征。
  • 无局灶综合征或抗体阴性的局灶综合征患者预后良好(89%)。
  • 抗GAD或抗细胞表面抗体阳性者治疗反应和预后好(100%),其他抗体阳性者预后差(71%)。

核心结论

  • ICI-iE总体预后良好,致死事件率低,但未检测到的副肿瘤性脑炎综合征被ICI触发时预后最差。

研究设计与样本

  • 系统综述纳入PubMed和Web of Knowledge数据库2000年6月至2020年4月的英文文献病例系列(n=77)及单中心医疗记录(n=5),共82例患者。

主要发现

  • 82例患者中男性52例(63%),中位年龄61.0岁(IQR 52.5-70.0)。
  • 局灶综合征39例(48%),脑膜脑炎36例(44%),无法分类7例(9%)。
  • 23例局灶综合征和1例无法分类患者检出神经元自身抗体,其中17/24(71%)为针对细胞内抗原的副肿瘤抗体。
  • 无局灶综合征或抗体阴性的局灶综合征患者预后良好(49/55,89%)。
  • 抗GAD或抗细胞表面抗体阳性者治疗反应和预后好(100%),其他抗体阳性者预后差(17/24,71%)。

关键数值与推荐

  • 抗神经元抗体(13/24 [54%] vs 5/41 [12%];P < .001)、局灶综合征(16/39 [41%] vs 4/43 [9%];P = .001)和MRI异常(14/39 [36%] vs 4/32 [13%];P = .02)与不良预后相关。
  • 发热(21/23 [91%] vs 41/59 [70%];P = .04)和脑脊液炎症改变较多(30/31 [97%] vs 21/33 [64%];P = .001)与较好预后相关。

临床怎么用

  • 临床应系统检测自身抗体,结合临床表现(局灶综合征、发热、脑脊液炎症)评估预后并指导治疗策略。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Encephalitis is a severe immune-related adverse event secondary to treatment with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) ranges from disease that resolves fully to lethal forms. Moreover, ICIs may unmask a paraneoplastic encephalitis. To our knowledge, the factors associated with ICI-iE prognosis are unknown. OBJECTIVES: To evaluate the presentation of ICI-iE and to identify features helpful in assessing outcomes. EVIDENCE REVIEW: This systematic review pooled case series from the published literature (n = 77) and medical records from 1 center (n = 5) to assess the association between the form of ICI-iE presentation and its prognosis. Eligibility criteria included references identified by searches of PubMed and Web of Knowledge databases in the English literature from June 2000 (first patient dose of ipilimumab) to April 17, 2020, that examined patients with encephalitis with presumed autoimmune etiologic features induced by ICIs. Information regarding clinical, cerebrospinal fluid, and neuroimaging (magnetic resonance imaging) features, as well as treatment given, were extracted. FINDINGS: A total of 82 patients (52 men [63%]; median age, 61.0 years [interquartile range, 52.5-70.0 years]) were included. Most patients presented with focal syndromes (39 [48%]) or meningoencephalitis (36 [44%]). Seven patients (9%) had nonclassifiable ICI-iE. Neuronal autoantibodies were detected in 23 patients with focal syndromes and 1 patient with nonclassifiable ICI-iE. Most autoantibodies were onconeuronal (17 of 24 [71%]), targeting intracellular antigens. Patients without a focal syndrome or with a negative-antibody focal syndrome had a good prognosis (49 of 55 [89%]). Among patients with autoantibodies, those with anti-glutamic acid decarboxylase or anticell surface responded to treatment and had a favorable prognosis (100%). However, patients with other autoantibodies had poor outcomes (17 of 24 [71%]). Antineuronal autoantibodies (13 of 24 [54%] vs 5 of 41 [12%]; P < .001), focal syndrome (16 of 39 [41%] vs 4 of 43 [9%]; P = .001), and abnormal magnetic resonance imaging findings (14 of 39 [36%] vs 4 of 32 [13%]; P = .02) were associated with poor outcomes. Conversely, fever (21 of 23 [91%] vs 41 of 59 [70%]; P = .04) and more inflammatory changes in cerebrospinal fluid (30 of 31 [97%] vs 21 of 33 [64%]; P = .001) were associated with a better prognosis. CONCLUSIONS AND RELEVANCE: Immune checkpoint inhibitors may induce mainly 2 different encephalitic syndromes: a focal limbic or extralimbic encephalitis and a meningoencephalitis. Immune checkpoint inhibitor-induced encephalitis is associated with an overall favorable outcome, with a low rate of fatal events. An undetected preexisting paraneoplastic encephalitic syndrome may be triggered by ICIs, and this type of syndrome has the worst outcome among all the different types of ICI-induced encephalitis syndromes. Clinical presentation and systematic measurement of autoantibodies will be a helpful guide for the therapeutic strategy and for counseling regarding prognosis.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Velasco R, Villagrán M, Jové M, et al. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. JAMA Neurol. 2021. PMID: 33720308. doi:10.1001/jamaneurol.2021.0249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。